Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life

Miaskowski, Christine; Mastick, Judy; Paul, Steven M.; Abrams, Gary; Cheung, Steven W.; Sabes, Jennifer Henderson; Kober, Kord M.; Schumacher, Mark; Conley, Yvette P.; Topp, Kimberly; Smoot, Betty; Mausisa, Grace; Mazor, Melissa; Wallhagen, Margaret; Levine, Jon D.

doi:10.1007/s11764-017-0662-8

Cited by 59 publications

(59 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that the number of cancer survivors in the United States is expected to reach 22.1 million by 2030, an increased emphasis is being placed on the evaluation of persistent adverse effects associated with its treatment . Persistent fatigue, anxiety, depression, pain, sleep disturbance, and cognitive deficits are extremely common, often co‐occur, and result in significant decrements in survivors' functional status and quality of life . Given the growing number of cancer survivors, as well as recent reports of the negative impact of persistent symptoms, a detailed evaluation of the symptom experience of these individuals is warranted.…”

Section: Introductionmentioning

confidence: 99%

Perceived stress is associated with a higher symptom burden in cancer survivors

Mazor

Paul

Chesney

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

Background Although multiple co‐occurring symptoms are a significant problem for cancer survivors, to the authors' knowledge little is known regarding the phenotypic characteristics associated with a higher symptom burden. The objectives of the current study were to evaluate the occurrence, severity, and distress associated with 32 symptoms and examine the phenotypic and stress characteristics associated with a higher symptom burden. Methods A total of 623 cancer survivors completed a demographic questionnaire, as well as measures of functional status, comorbidity, and global (Perceived Stress Scale) and cancer‐related (Impact of Event Scale–Revised) stress. The Memorial Symptom Assessment Scale was used to evaluate symptom burden. Multiple linear regression analysis was used to determine the phenotypic characteristics associated with a higher symptom burden. Results The mean number of symptoms was 9.1 (±5.2). The most common, severe, and distressing symptoms were lack of energy, problems with sexual interest/activity, and hair loss, respectively. Poorer functional status, a higher level of comorbidity, and a history of smoking as well as higher Perceived Stress Scale and Impact of Event Scale–Revised scores were associated with a higher symptom burden. The overall model explained approximately 45.6% of the variance in symptom burden. Conclusions Although cancer survivors report a high number of co‐occurring symptoms of moderate severity and distress, in the current study, no disease or treatment characteristics were found to be associated with a higher symptom burden. Clinicians need to assess for general and disease‐specific stressors and provide referrals for stress management interventions. Future studies need to examine the longitudinal relationships among symptom burden, functional status, and level of comorbidity, as well as the mechanisms that underlie the associations between stress and symptom burden.

show abstract

Section: Introductionmentioning

confidence: 99%

Perceived stress is associated with a higher symptom burden in cancer survivors

Mazor

Paul

Chesney

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…As chemotherapeutic drugs were carboplatin, cyclophosphamide and doxorubicin, which can damage permanently organ of hearing as described [3,14,15]. Investigators described that platinnun drugs affected 14% of cancer treatment´s survivors once these drugs are considered not only ototoxic, but neurotoxic [15]. The incidence of hearing loss for head and neck cancer, in our study was 28.8% therefore investigators reported an incidence of 27% to 95% [13].…”

Section: Discussionmentioning

confidence: 49%

“…In our research, all patients received, and 3D radiotherapy as prescribed by oncologist. As chemotherapeutic drugs were carboplatin, cyclophosphamide and doxorubicin, which can damage permanently organ of hearing as described [3,14,15]. Investigators described that platinnun drugs affected 14% of cancer treatment´s survivors once these drugs are considered not only ototoxic, but neurotoxic [15].…”

Section: Discussionmentioning

confidence: 99%

“…As described, chemotherapy uses drugs like Cisplatin, Carboplatin, Oxaliplatin, and Nedaplatin, which have been widely chosen as an efficient treatment in oncology. Moreover, platinnun group is the most devastating drug to inner ear [3,14,15]. It has toxic side effects to the peripheral auditory system which lead to hearing loss with an impaired social communication [3].…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy with platinnun and / or taxane compounds develops neurotoxicity, which induces neuropathy. Investigators reported hearing loss, balance problems and tinnitus with significant decrement of quality of life [15].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cancer treatment: changes in hearing thresholds

Machado¹,

Amaral²,

Aguiar³

et al. 2018

Oncol Res Rev

View full text Add to dashboard Cite

Purpose: Evaluate changes in hearing thresholds in patients undergoing cancer treatment.Method: Prospective, longitudinal study carried out at Cancer Center of a Sergipe´s public hospital, Brazil. Audiological evaluation (Conventional Pure Tone Audiometry) have been performed in 20 patients following eight weeks of cancer treatment (reference exam) and 20 weeks (sequential exam) of treatment. All survivors had normal hearing thresholds before cancer treatment. The procedure has been approved by the Ethics in Research Committee, under protocol # 33665014.7.0000.5546.Results: Head and neck cancer displayed oncology highest incidence (35%). Referential exam, eight weeks before treatment, displayed 15% with sensorineural hearing loss and 17.5% at second tests. It was observed a slight worsening for all test frequencies of referential and sequential exam. Tinnitus was the biggest complaint (81.3%), but there was no statistic correlation between hearing loss (p=0.89). Conclusion:Hearing monitoring form this small sample suggest chemotherapy and radiotherapy treatments can have a detrimental effect on hearing thresholds significate for 2 to 8kHz eight weeks after cancer treatment and 4 to 8kHz 20 weeks before.

show abstract